Intersect ENT Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT or view top-rated stocks.

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Intersect ENT is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Intersect ENT.

Intersect ENT will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Intersect ENT, Inc. (NASDAQ:XENT) released its quarterly earnings data on Thursday, November, 5th. The medical equipment provider reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.10. The medical equipment provider earned $22.72 million during the quarter, compared to analyst estimates of $21.78 million. Intersect ENT had a negative net margin of 71.96% and a negative trailing twelve-month return on equity of 55.81%. The firm's revenue was down 5.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.41) earnings per share.
View Intersect ENT's earnings history.

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 13.2% and is now trading at $24.33.
View which stocks have been most impacted by COVID-19.

Intersect ENT issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.7-28.1 million, compared to the consensus revenue estimate of $27.67 million.

8 Wall Street analysts have issued 1-year price targets for Intersect ENT's stock. Their forecasts range from $10.00 to $32.00. On average, they anticipate Intersect ENT's share price to reach $23.00 in the next twelve months. This suggests that the stock has a possible downside of 5.5%.
View analysts' price targets for Intersect ENT or view top-rated stocks among Wall Street analysts.

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Intersect ENT include NuVasive (NUVA), Merit Medical Systems (MMSI), AtriCure (ATRC), Inovio Pharmaceuticals (INO), Pulmonx (LUNG), Axonics Modulation Technologies (AXNX), Silk Road Medical (SILK), Cardiovascular Systems (CSII), Luminex (LMNX), GenMark Diagnostics (GNMK), Alphatec (ATEC), Atrion (ATRI), MiMedx Group (MDXG), OrthoPediatrics (KIDS) and Cerus (CERS).
View all of XENT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), Costamare (CMRE), Mimecast (MIME), EOG Resources (EOG), Air Transport Services Group (ATSG), BioCryst Pharmaceuticals (BCRX), Gilead Sciences (GILD) and AbbVie (ABBV).

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Intersect ENT's stock is owned by a variety of retail and institutional investors. Top institutional investors include Artisan Partners Limited Partnership (9.07%), BlackRock Inc. (8.82%), Jennison Associates LLC (3.19%), Nuveen Asset Management LLC (2.17%), Northern Trust Corp (1.28%) and JPMorgan Chase & Co. (1.04%). Company insiders that own Intersect ENT stock include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Robert H Binney, Jr, Susan P Stimson and Thomas A West.
View institutional ownership trends for Intersect ENT.

XENT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., JPMorgan Chase & Co., Voloridge Investment Management LLC, Northern Trust Corp, Gabelli Funds LLC, Great Lakes Advisors LLC, Russell Investments Group Ltd., and State of Wisconsin Investment Board.
View insider buying and selling activity for Intersect ENT or view top insider-selling stocks.

XENT stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, BlackRock Inc., Morgan Stanley, Nuveen Asset Management LLC, Jennison Associates LLC, Gyon Technologies Capital Management LP, HighTower Advisors LLC, and Renaissance Technologies LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT or or view top insider-buying stocks.

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of XENT stock can currently be purchased for approximately $24.33.

Intersect ENT has a market capitalization of $796.05 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

Intersect ENT employs 402 workers across the globe.

The official website for Intersect ENT is www.intersectent.com.

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]